Cowan, Juthaporn
Bonagura, Vincent R.
Lugar, Patricia L.
Maglione, Paul J.
Patel, Niraj C.
Vinh, Donald C.
Hofmann, Jutta H.
Praus, Michaela
Rojavin, Mikhail A. http://orcid.org/0000-0002-9010-2865
Funding for this research was provided by:
CSL Behring
Article History
Received: 15 June 2020
Accepted: 25 September 2020
First Online: 6 October 2020
Compliance with Ethical Standards
:
: JC has received research funding from CSL Behring and Octapharma and is a clinical trial site investigator for Takeda. VRB has served as a speaker for CSL Behring and Takeda. PLL is a clinical trial site investigator for CSL Behring and Takeda. PJM has received research funding from the National Institutes of Health, the AAAAI Foundation, Boston University, Takeda, and Horizon Pharma. NCP has served as a speaker for CSL Behring and Takeda; has received research funding from CSL Behring and Takeda; and has served as an advisory board member for Horizon Therapeutics. DCV has received research funding from the Fonds de la recherche en santé du Quebec, Canadian Institutes of Health Research, the U.S. Department of Defense, the Jeffrey Modell Foundation, La Fondation du Grand Défi Pierre Lavoie, and CSL Behring; has served as a speaker for CSL Behring and Avir Pharma; and has received clinical trial funding from CSL Behring and Cidara Therapeutics. MAR, MP, and JHH are employees of CSL Behring and own CSL Behring shares.
: All procedures performed in this study were in accordance with the ethical standards of the institutional review boards at each study site and with the 1964 Declaration of Helsinki and its later amendments. The clinical study protocol and all amendments were approved by the Independent Ethics Committees or the Institutional Review Boards of the participating centers.
: Informed consent was obtained from all patients or their relatives or legally accepted representatives.
: The funder had the following involvement with the study: study design, data collection and analysis, and decision to publish.